Navigation Links
Children's Hospital Oakland Standardizes to Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Technology

IRVINE, Calif., Sept. 1 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Children's Hospital & Research Center Oakland has completed its system-wide conversions to Masimo Rainbow SET Pulse CO-Oximetry technology. Standardizing to Masimo Rainbow SET makes Children's Hospital Oakland the first children's hospital to pioneer new continuous noninvasive blood monitoring capabilities hospital-wide--allowing earlier and better clinical decisions without the intermittent pain and wait associated with drawing blood.

By converting to Masimo Rainbow SET, Children's Hospital Oakland clinicians will gain all the benefits and Measure-Through Motion capabilities of Masimo SET pulse oximetry, along with the breakthrough innovation of the first-ever continuous and noninvasive hemoglobin monitoring (SpHb(TM)) technology. Noninvasive hemoglobin will allow clinicians at Children's to detect and treat chronic or acute anemia earlier, identify internal bleeding sooner, and more effectively manage blood transfusions for their patients. The ability to immediately detect and treat potentially life-threatening conditions earlier may help save lives and improve patient outcomes.

Katie Sabato, MS, RRT, director of Respiratory Care, Pulmonary Function & Sleep Labs at Children's Hospital Oakland, stated, "All of our efforts are focused on helping kids get better, which requires a very special level of care and some of the world's most sophisticated technology. Masimo Rainbow SET will allow us to measure critical components of a child's blood quickly and easily, without the pain of a needle stick and the discomfort of having blood drawn. It's also a great example of how we leverage advanced technology and innovative care solutions to improve comfort and care and speed-up a child's recovery."

Masimo Founder and CEO, Joe E. Kiani, stated, "We are proud of our relationship with Children's Hospital Oakland. Children's was one of the first children's hospitals to convert to Masimo SET years ago and, with a history of leadership in the practice of neonatal and pediatric care, they are continuing to lead new efforts to transform pediatric patient care with their conversion to Masimo Rainbow SET Pulse CO-Oximetry. We are delighted that they have chosen to significantly impact the care and treatment of children and advance the practice of medicine using our noninvasive and continuous Rainbow platform."

Masimo Rainbow SpHb is transforming the way patients are managed in the operating room, intensive care unit and emergency department, where clinicians are reporting earlier identification of necessary blood transfusions, reduction in unnecessary transfusions and invasive tests, increased patient safety, and improved clinical outcomes.

Amit Gupta, M.D., pediatric anesthesiologist at Children's Hospital & Research Center Oakland, stated, "Preserving safe hemoglobin levels are always a particular concern for pediatric patients who already have very little hemoglobin to spare. With Masimo Rainbow SET in the peri-operative setting we can noninvasively detect internal bleeding, fluid responsiveness, oxygen saturation, pulse rate, and perfusion--all in a matter of seconds. Having this level of physiological detail immediately available at our fingertips is a tremendous benefit that helps to speed patient assessment, treatment, care, and the safe return to optimal health."

Children's Hospital & Research Center Oakland is a regional and global resource for advanced pediatric care, research and medical education. With more than 200,000 patient visits per year, Children's has Northern California's most active pediatric trauma center, the region's busiest pediatric intensive care unit, and one of the largest sickle cell treatment and research centers in the world.

About Children's Hospital & Research Center Oakland

Children's Hospital & Research Center Oakland is Northern California's only freestanding and independent children's hospital. Children's is a leader in many pediatric specialties including neonatology, cardiology, neurosurgery and intensive care. The hospital is a designated Level 1 pediatric trauma center and has the largest pediatric critical care facility in the region. Children's Hospital has 190 licensed beds, 201 hospital-based physicians in 30 specialties, more than 2,600 employees and an annual operating budget of $312 million. Children's research arm, Children's Hospital Oakland Research Institute (CHORI), is internationally renowned for taking state-of-the-art basic and clinical research to the bedside with interventions for treating and preventing human disease. CHORI has 300 staffers, a budget of about $50 million, and is ranked among the nation's top 10 research centers in National Institutes of Health funding to children's hospitals. CHORI is a leader in translational research, developing new vaccines for infectious diseases, and discovering new treatment protocols for previously fatal or debilitating conditions including cancer, sickle cell anemia, thalassemia, diabetes, asthma, HIV/AIDS, pediatric obesity, nutritional deficiencies, birth defects, hemophilia and cystic fibrosis. For more information, go to

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results, risks related to our belief that Masimo Rainbow SET will provide sufficient sensitivity and specificity to detect physiological abnormalities in real-time, enabling clinicians to detect and identify potentially life-threatening conditions earlier and make better clinical and treatment decisions for their patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

    Media Contacts:
    Dana Banks
    Masimo Corporation
    +1 (949) 297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
2. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
3. SmartGenes Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital
4. St. Johns Hospital Acquires Latest Technology in Robotic-Assisted Surgery
5. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
6. Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance
7. USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk
8. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
9. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
10. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
11. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
Post Your Comments:
(Date:11/24/2015)... PHILADELPIA, PA (PRWEB) , ... November 24, 2015 , ... ... young entrepreneurs at competitive events in five states to develop and pitch their BIG ... student projects from each state are competing for votes to win the title of ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list of ... OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic ...
Breaking Biology Technology:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):